148 related articles for article (PubMed ID: 36170166)
1. Local treatment in patients with hereditary breast cancer: decision-making process in low-, moderate-, high-penetrance pathogenic germline mutation carriers.
Sibilio A; Curcio A; Toesca A; Rossi EMC; Corso G
Curr Opin Oncol; 2022 Nov; 34(6):614-622. PubMed ID: 36170166
[TBL] [Abstract][Full Text] [Related]
2. Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline.
Tung NM; Boughey JC; Pierce LJ; Robson ME; Bedrosian I; Dietz JR; Dragun A; Gelpi JB; Hofstatter EW; Isaacs CJ; Jatoi I; Kennedy E; Litton JK; Mayr NA; Qamar RD; Trombetta MG; Harvey BE; Somerfield MR; Zakalik D
J Clin Oncol; 2020 Jun; 38(18):2080-2106. PubMed ID: 32243226
[TBL] [Abstract][Full Text] [Related]
3. ASTRO Radiation Therapy Summary of the ASCO-ASTRO-SSO Guideline on Management of Hereditary Breast Cancer.
Trombetta MG; Dragun A; Mayr NA; Pierce LJ
Pract Radiat Oncol; 2020; 10(4):235-242. PubMed ID: 32471709
[TBL] [Abstract][Full Text] [Related]
4. PARP-inhibitors for BRCA1/2-related advanced HER2-negative breast cancer: A meta-analysis and GRADE recommendations by the Italian Association of Medical Oncology.
Miglietta F; Cinquini M; Dieci MV; Cortesi L; Criscitiello C; Montemurro F; Del Mastro L; Zambelli A; Biganzoli L; Levaggi A; Delle Piane C; Marchiò C; Calabrese M; Fortunato L; Franco P; Meduri B; Fittipaldo VA; Gori S
Breast; 2022 Dec; 66():293-304. PubMed ID: 36379199
[TBL] [Abstract][Full Text] [Related]
5. Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D.
Graffeo R; Rana HQ; Conforti F; Bonanni B; Cardoso MJ; Paluch-Shimon S; Pagani O; Goldhirsch A; Partridge AH; Lambertini M; Garber JE
Breast; 2022 Oct; 65():32-40. PubMed ID: 35772246
[TBL] [Abstract][Full Text] [Related]
6. ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes.
Guillem JG; Wood WC; Moley JF; Berchuck A; Karlan BY; Mutch DG; Gagel RF; Weitzel J; Morrow M; Weber BL; Giardiello F; Rodriguez-Bigas MA; Church J; Gruber S; Offit K; ;
J Clin Oncol; 2006 Oct; 24(28):4642-60. PubMed ID: 17008706
[TBL] [Abstract][Full Text] [Related]
7. Margins for breast-conserving surgery with whole-breast irradiation in stage I and II invasive breast cancer: American Society of Clinical Oncology endorsement of the Society of Surgical Oncology/American Society for Radiation Oncology consensus guideline.
Buchholz TA; Somerfield MR; Griggs JJ; El-Eid S; Hammond ME; Lyman GH; Mason G; Newman LA
J Clin Oncol; 2014 May; 32(14):1502-6. PubMed ID: 24711553
[TBL] [Abstract][Full Text] [Related]
8. Breast cancer under age 40: a different approach.
Ribnikar D; Ribeiro JM; Pinto D; Sousa B; Pinto AC; Gomes E; Moser EC; Cardoso MJ; Cardoso F
Curr Treat Options Oncol; 2015 Apr; 16(4):16. PubMed ID: 25796377
[TBL] [Abstract][Full Text] [Related]
9. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R
Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561
[TBL] [Abstract][Full Text] [Related]
10. The role of novel poly (ADP-ribose) inhibitors in the treatment of locally advanced and metastatic Her-2/neu negative breast cancer with inherited germline BRCA1/2 mutations. A review of the literature.
Pop L; Suciu I; Ionescu O; Bacalbasa N; Ionescu P
J Med Life; 2021; 14(1):17-20. PubMed ID: 33767780
[TBL] [Abstract][Full Text] [Related]
11. Hereditary breast cancer: translation into clinical practice of recent American Society of Clinical Oncology, American Society of Radiation Oncology, and Society of Surgical Oncology recommendations.
Corso G; Magnoni F
Eur J Cancer Prev; 2021 Jul; 30(4):311-314. PubMed ID: 32898012
[TBL] [Abstract][Full Text] [Related]
12. Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update.
Henry NL; Somerfield MR; Dayao Z; Elias A; Kalinsky K; McShane LM; Moy B; Park BH; Shanahan KM; Sharma P; Shatsky R; Stringer-Reasor E; Telli M; Turner NC; DeMichele A
J Clin Oncol; 2022 Sep; 40(27):3205-3221. PubMed ID: 35759724
[TBL] [Abstract][Full Text] [Related]
13. Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care.
Graffeo R; Livraghi L; Pagani O; Goldhirsch A; Partridge AH; Garber JE
Breast Cancer Res Treat; 2016 Dec; 160(3):393-410. PubMed ID: 27734215
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant PARP Inhibitors in Patients With High-Risk Early-Stage HER2-Negative Breast Cancer and Germline
Tung NM; Zakalik D; Somerfield MR;
J Clin Oncol; 2021 Sep; 39(26):2959-2961. PubMed ID: 34343058
[No Abstract] [Full Text] [Related]
15. Poly (ADP-ribose) Polymerase Inhibition in Patients with Breast Cancer and BRCA 1 and 2 Mutations.
Jerez Y; Márquez-Rodas I; Aparicio I; Alva M; Martín M; López-Tarruella S
Drugs; 2020 Feb; 80(2):131-146. PubMed ID: 31823331
[TBL] [Abstract][Full Text] [Related]
16. BRCA1 and BRCA2 mutations and clinical interpretation in 398 ovarian cancer patients: comparison with breast cancer variants in a similar population.
Cardoso FC; Goncalves S; Mele PG; Liria NC; Sganga L; Diaz Perez I; Podesta EJ; Solano AR
Hum Genomics; 2018 Aug; 12(1):39. PubMed ID: 30103829
[TBL] [Abstract][Full Text] [Related]
17. Genetic counselling and testing of susceptibility genes for therapeutic decision-making in breast cancer-an European consensus statement and expert recommendations.
Singer CF; Balmaña J; Bürki N; Delaloge S; Filieri ME; Gerdes AM; Grindedal EM; Han S; Johansson O; Kaufman B; Krajc M; Loman N; Olah E; Paluch-Shimon S; Plavetic ND; Pohlodek K; Rhiem K; Teixeira M; Evans DG
Eur J Cancer; 2019 Jan; 106():54-60. PubMed ID: 30471648
[TBL] [Abstract][Full Text] [Related]
18. Clinical implications of germline mutations in breast cancer genes: RECQL.
Bowden AR; Tischkowitz M
Breast Cancer Res Treat; 2019 Apr; 174(3):553-560. PubMed ID: 30610487
[TBL] [Abstract][Full Text] [Related]
19. PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.
Turk AA; Wisinski KB
Cancer; 2018 Jun; 124(12):2498-2506. PubMed ID: 29660759
[TBL] [Abstract][Full Text] [Related]
20. Germline Genetic Testing in Breast Cancer: Systemic Therapy Implications.
Bhardwaj PV; Abdou YG
Curr Oncol Rep; 2022 Dec; 24(12):1791-1800. PubMed ID: 36255604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
